Immunother Ltd to accelerate Immunotherapy programs in Shenzhen
07/08/2020

Immunother Ltd, a Shenzhen-based biotechnology company today announced its immuno-oncology programs to obtain key data on accuracy, efficacy and safety.

Online PR News – 08-July-2020 – SHENZHEN – Headquartered in Hong Kong, their Shenzhen based scientists and bioengineer’s are instrumental in the development of synthetic biology, gene editing and single-cell sequencing technologies.

Immunother Ltd’s Chairman & Chief Scientist, Mr. Geoffrey Marcus PhD commented on the development programs saying "Immunotherapies today are challenged by the complexities of the immune system, the scope and speed at which cells need to be analyzed and manipulated, and the specific targets that are identified in different diseases.”

"We at Immunother Ltd are developing a meticulous approach to immunotherapy that will overcome these limitations. While the immune system is the most powerful disease-fighting tool in the human body, almost all immune-oriented therapeutic approaches suffer from an inability to distinguish between disease-causing immune cells and disease-fighting immune cells,” added Geoffrey Marcus, Chairman & Chief Scientist of Immunother Ltd.

About Us - Immunother

Immunother Limited Company is a privately held Shenzen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.

Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.